K Number
K212733
Date Cleared
2023-06-06

(645 days)

Product Code
Regulation Number
878.4810
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Diode laser therapy device is intended for delivery of laser light to soft tissue in the contact mode during surgical procedures. The device's 980mm laser is generally indicated for use in incision, vaporization, ablation, hemostasis or coagulation of soft tissue in ear, nose and throat and oral surgery (otolaryngology), dental procedures, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, urology, gynecology. The device is further indicated for laser assisted lipolysis. The device's intended for delivery of laser light to soft tissue in non-contact mode during general surgery procedures, indicated for the treatment of reflux of the saphenous veins associated with varicose veins and varicosities.

Device Description

The diode laser generates a 980nm wavelength laser to act on a target tissue to achieve resection, hemostasis, ablation, and coaqulation of the target tissue. The diode laser generates a 1470 nm wavelength laser that acts on the water molecules of the target tissue to achieve the function of treatment of reflux of the saphenous veins associated with varicose veins and varicosities. The Diode laser therapy device has following characteristics:

  • Dual wavelengths A
  • A Temperature monitoring system
AI/ML Overview

This document is a 510(k) summary for the Diode laser therapy device, and it details the device's characteristics, intended use, and comparison to predicate devices, but it does not specify acceptance criteria or a study designed to prove the device meets those criteria in the typical sense of a clinical performance study. Instead, the document focuses on demonstrating substantial equivalence to predicate devices through technical, performance, and safety comparisons.

Here's an analysis of the provided text based on your request, highlighting what is and isn't available:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state "acceptance criteria" in the form of performance thresholds that the device was required to meet for clearance. Instead, it relies on demonstrating that the proposed device is "as safe, as effective, and performs as well as or better than" the legally marketed predicate devices. The "reported device performance" is presented through technical specifications and safety comparisons to these predicate devices.

Table: Comparison of Proposed Device Performance to Predicate Devices (Implied Acceptance Based on Substantial Equivalence)

ItemImplied Acceptance (Predicate Performance)Proposed Device Performance (Reported)
Intended Use (980nm)Incision, excision, vaporization, ablation, hemostasis, or coagulation of soft tissue in various specialties, including laser-assisted lipolysis. (Based on K081015)Incision, excision, vaporization, ablation, hemostasis, or coagulation of soft tissue in otolaryngology, dental procedures, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, urology, gynecology, and laser-assisted lipolysis.
Intended Use (1470nm)Treatment of reflux of saphenous veins associated with varicose veins and varicosities. (Based on K073063)Treatment of reflux of the saphenous veins associated with varicose veins and varicosities.
Wavelength980 nm, 1470 nm980nm±5nm, 1470nm±10nm
Max Power (980nm)15 Watt (Predicate K081015)16W/980nm±20%
Max Power (1470nm)15 Watt (Predicate K073063)4.5W/1470nm±20%
Aiming Beam635 nm, red 4 mW, user controlled intensity (Predicates)650 nm, red 0.5 mW, user controlled intensity
Treatment ModeContinuous or PulsedContinuous or Pulsed, Single
BiocompatibilityCytotoxicity, Irritation, Sensitization (Comply with ISO 10993-5, ISO 10993-10)Cytotoxicity, Irritation, Sensitization, Acute systemic toxicity, Pyrogen test, In vitro hemolytic test (Comply with ISO 10993-5, ISO 10993-10, ISO 10993-11, ISO 10993-4). (More extensive testing than predicates).
Electrical SafetyComply with IEC 60601-1, IEC 60825-1, IEC 60601-2-22Comply with IEC 60601-1:2005+A1:2012, IEC 60825-1:2014, IEC 60601-2-22:2007+A1:2012
EMCComply with IEC 60601-1-2Comply with IEC 60601-1-2:2014

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

The document explicitly states "No clinical study implemented for the Diode laser therapy device." Therefore, there is no test set in the sense of patient data, nor data provenance information related to clinical performance. The assessment is based on non-clinical (bench) testing and comparison to predicate devices. For the 1470nm max power, it mentions "clinical survey data, and clinical literature" were collected to support efficacy, but no details on sample size or provenance are given for this supporting evidence.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable. No clinical test set.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. No clinical test set.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is a laser therapy device, not an AI-assisted diagnostic or interpretive device.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This is a medical device, not an algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Not applicable. No clinical study with a traditional "ground truth" was performed for the device itself. For the "clinical survey data and clinical literature" mentioned regarding the 1470nm laser power, the type of "ground truth" used there would depend on the nature of those external studies/surveys, but no details are provided.

8. The sample size for the training set

Not applicable. There is no mention of a training set as this is not an AI/machine learning device. The assessment is based on non-clinical testing and comparison to predicate devices.

9. How the ground truth for the training set was established

Not applicable. No training set.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.

June 6, 2023

Beijing Star New Tech Co., Ltd. % Boyle Wang General Manager Shanghai Truthful Information Technology Co., Ltd. Room608,No.738,Shangcheng Rd.,Pudong Shanghai, Shanghai 200120 China

Re: K212733

Trade/Device Name: Diode laser therapy device Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX Dated: April 28, 2023 Received: May 1, 2023

Dear Boyle Wang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS)

regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Jianting Wang -S

Jianting Wang Acting Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K212733

Device Name Diode laser therapy device

Indications for Use (Describe)

The Diode laser therapy device is intended for delivery of laser light to soft tissue in the contact mode during surgical procedures. The device's 980mm laser is generally indicated for use in incision, vaporization, ablation, hemostasis or coagulation of soft tissue in ear, nose and throat and oral surgery (otolaryngology), dental procedures, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, urology, gynecology. The device is further indicated for laser assisted lipolysis. The device's intended for delivery of laser light to soft tissue in non-contact mode during general surgery procedures, indicated for the treatment of reflux of the saphenous veins associated with varicose veins and varicosities.

Type of Use (Select one or both, as applicable)

Deposition Use (Part 21 CFR 601.21 and D)
The Concordance (21 CFR

| > Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

510(k) number: K212733

This summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of SMDA 1990 and 21 CFR 807.92.

1.0 Submitter's information

Name: Beijing Star New Tech Co., Ltd. Address: Room 618, Block C, Jinri Science Park, No. 26 Jinyuan Road, Daxing District, Beijing, China Phone Number: 86-10-61271282 Fax number: 86-10-61271282 Contact: Liang Zhongdong Date of Preparation: Jun.02, 2023

Prior submissions

This is the first submission, there is no prior submission.

Designated Submission Correspondent

Mr. Boyle Wang Shanghai Truthful Information Technology Co., Ltd. Room 608, No. 738 Shangcheng Rd., Pudong Shanghai, 200120 China Tel: +86-21-50313932 Email: Info@truthful.com.cn

2.0 Device information

Trade name:Diode laser therapy device
Common name:Powered Laser Surgical Instrument
Regulation name:Laser surgical instrument for use in general and plastic surgeryand in dermatology
Model(s):ST-AR.

3.0 Classification

Production code: GEX Regulation number: 21 CFR 878.4810 Classification: Class II Panel: General & Plastic Surgery

4.0 Predicate device information

{4}------------------------------------------------

510(k) Number: K081015 Product Name: Ceralas Diode 980nm Laser System Manufacturer: Biolitec, Inc.

510(k) Number: K073063 Product Name: 15W Ceralas Diode 1470nm Laser System Manufacturer: Biolitec, Inc.

5.0 Indication for Use Statement

The Diode laser therapy device is intended for delivery of laser light to soft tissue in the contact and non contact mode during surgical procedures. The device's 980nm laser is generally indicated for use in incision, excision, vaporization, ablation, hemostasis or coagulation of soft tissue in ear, nose and throat and oral surgery (otolaryngology), dental procedures, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, urology, gynecology. The device is further indicated for laser assisted lipolysis. The device's 1470nm laser is intended for delivery of laser light to soft tissue in non-contact mode during general surgery procedures, indicated for the treatment of reflux of the saphenous veins associated with varicose veins and varicosities.

6.0 Device description

The diode laser generates a 980nm wavelength laser to act on a target tissue to achieve resection, hemostasis, ablation, and coaqulation of the target tissue. The diode laser generates a 1470 nm wavelength laser that acts on the water molecules of the target tissue to achieve the function of treatment of reflux of the saphenous veins associated with varicose veins and varicosities. The Diode laser therapy device has following characteristics:

  • Dual wavelengths A
  • A Temperature monitoring system

7.0 Non-Clinical Test Conclusion

ltemTechnical specification
Wavelength980nm±5nm, 1470nm±5nm
Max Power16W/980nm±20%, 4.5W/1470nm±20%, 0.5mw/650nm
Security LevelClass IV type B
Laser Output ModeContinuous, Pulse, Single.
Pulse Width0.05ms-1s (stepping 0.05, 0.1ms)
CoolingAir Cooling
Size38×46.5×22.5cm
Net Weight8KG
FuseØ5×25, 2A
Laser Output Power16W/980nm±10%, 4.5W/1470nm±10%

Table 1 - Product Technical Specification

{5}------------------------------------------------

0.05mw/650nm
Fiber DiameterΦ400
Aiming beam650 nm, red 0.5 mW, user controlled intensity
Treatment modeContinuous, Pulse, Single.

Table 2 - Biocompatibility testing for components contacting patients

ItemProposed DeviceResult
CytotoxicityUnder the conditions of the study, the device is noncytotoxic.Pass
IrritationUnder the conditions of the study, the device is nonirritating.Pass
SensitizationUnder the conditions of the study, the device is nonsensitizingPass
Aucte systemic toxicity,Under the conditions of the study, the device does show aucte systemic toxicityPass
Pyrogen testUnder the conditions of the study, the device does show pyrogenPass
In vitro hemolytic testUnder the conditions of the study, the device does show In vitro hemolytic riskPass

8.0 _Clinical Test Conclusion

No clinical study implemented for the Diode laser therapy device.

9.0 Technological Characteristic Comparison Table

{6}------------------------------------------------

ItemProposed devicePredicated deviceRemark
Product CodeGEXGEXGEXIdentical
Regulation No.21 CFR 878.481021 CFR 878.481021 CFR 878.4810Identical
ClassIIIIIIIdentical
Product nameDiode laser therapy deviceCeralas Diode 980nm Laser System15W Ceralas Diode 1470nmLaser System-
510(k) No.K212733K081015K073063-
ModelsST-ARD15D1470-
Intended useThe Diode laser therapy device isintended for delivery of laser light to softtissue in the contact and non contactmode during surgical procedures. Thedevice's 980nm laser is generallyindicated for use in incision, excision,vaporization, ablation, hemostasis orcoagulation of soft tissue in ear, nose andthroat and oral surgery (otolaryngology),dental procedures, gastroenterology,general surgery, dermatology, plasticsurgery, podiatry, urology, gynecology.The device is further indicated for laserassisted lipolysis.The Ceralas D 980 is intended fordelivery of laser light to soft tissue in thecontact or noncontact mode duringsurgical procedures, including viaendoscopes, introducers, or catheters.The Ceralas D 980 is generally indicatedfor incision, excision, vaporization,ablation, hemostasis, or coagulation ofsoft tissue in ear, nose and throat andoral surgery (otolaryngology), dentalprocedures, arthroscopy,gastroenterology, general surgery,dermatology, plastic surgery,podiatry, urology, gynecology,neurosurgery (peripheral nervoussystem), pulmonary surgery, andcardiothoracic surgery. and* Gap 1

{7}------------------------------------------------

ophthalmology. This Ceralas D 980 isspecifically indicated for laser assistedlipolysis.
The device's 1470nm laser is intendedfor delivery of laser light to soft tissue innon-contact mode during general surgeryprocedures, indicated for the treatment ofreflux of the saphenous veins associatedwith varicose veins and varicosities.The Ceralas D1470 is a diodelaser that is intended for deliveryof laser light to soft tissue innon-contact mode duringgeneral surgery procedures.The device is indicated for thetreatment of reflux of thesaphenous veins associatedwith varicose veins andvaricosities.Same
PatientPopulationAdultAdultAdultSame
  • Gap analysis:

Gap 1: The proposed device does not use with the endoscope, the indication of Arthroscopy, Cardiothoracic Surgery, Neurosurgery, treatment of reflux of the saphenous veins and varicosities, which the predicate device applies does not apply to the proposed device, less indication will not bring additional risks to the proposed device.

Gap 2: The proposed device defines specific contraindication which does not bring additional clinical risk for the product use.

Table 4- Performance Comparison

ItemProposed DevicePredicate DeviceRemark
Diode laser therapy deviceK212733Ceralas Diode 980nm Laser SystemK08101515W Ceralas Diode 1470nm Laser SystemK073063

{8}------------------------------------------------

Wavelength980nm±5nm,1470nm±10nm980 nm1470 nmSame
Output Power max.16W/980nm±20%,4.5W/1470nm±20%15 Watt15 Watt* Gap 2
Aiming beam650 nm, red 0.5 mW, usercontrolled intensity635 nm, red 4 mW, user controlledintensity635 nm, red 4 mW, user controlledintensity* Gap 3
Treatment modeContinuous or PulsedContinuous or PulsedContinuous or PulsedSame
Power supplyAC110V±11V, 60HZ110/220 V110/220 V* Gap 4
Interval980nm 1% ~ 100%,1470nm 2% ~100%,continuously adjustableenergy980nm 1% ~ 100%, continuouslyadjustable energy1470nm 2% ~100%, continuouslyadjustable energySame
Cooling systemAir cooledAir cooledAir cooledSame
Fiber (applied part)Sterile, for single useSingle use or repeated useSingle use or repeated use* Gap 5
  • Gap analysis:

Gap 2, the 980nm max power of the proposed device is close to the predicate device, which does not create additional risk to the product use. For 1470m max power of the proposed device is different to the predicate device, we collect clinical survey data, and clinical literature which can support the efficacy of the 4.5W is effective to realize its intended performance, the lower 4.5W can risks compared to predicate device.

Gap 3, the aiming beam of the two device are close, which difference does not create additional risks to the product clinical use.

Gap 4, the power supply range of the proposed device is included in the predicate device.

Gap 5, the fiber (applied part) of the proposed device is for single use, sterile, which will not create addtional risks compared to the equivalence device.

Table 5- Safety Comparison

ItemProposed DevicePredicate DeviceRemark
-------------------------------------------------

{9}------------------------------------------------

Diode laser therapy deviceCeralas Diode 980nm Laser15W Ceralas Diode 1470nm
SystemLaser System
K212733K081015K073063
Materialscontacting userFiberFiberFiberSame
Biocompatibility ofmaterialscontacting userCytotoxicity, Comply with ISO10993-5;Irritation, Sensitization, complywith ISO 10993-10;Aucte systemic toxicity,Pyrogen test comply with ISO10993-11;In vitro hemolytic test complywith ISO 10993-4.Cytotoxicity, Comply with ISO10993-5;Irritation, Sensitization, complywith ISO 10993-10Cytotoxicity, Comply with ISO10993-5;Irritation, Sensitization, complywith ISO 10993-10Gap 6
Electric safetyComply with IEC60601-1:2005+A1:2012, IEC60825-1:2014,IEC 60601-2-22:2007+A1:2012Comply with IEC 60601-1, IEC60825-1, IEC 60601-2-22Comply with IEC 60601-1, IEC60825-1, IEC 60601-2-22Same
EMCComply with IEC60601-1-2:2014Comply with IEC 60601-1-2Comply with IEC 60601-1-2Same
  • Gap analysis:

Gap 6: the proposed device implement more biccompatibility study for the device, which does not create additional risks for product use

{10}------------------------------------------------

10.0 Conclusion

The conclusion drawn from the nonclinical tests demonstrates that the subject device in 510(K) submission, the Diode laser therapy device is as safe, as effective, and performs as well as or better than the legally marketed predicate device cleared under K081015, K073063.

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.